Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mirum Pharmaceuticals, Inc. (MIRM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.36-0.12 (-0.49%)
At close: 04:00PM EDT
25.14 +0.78 (+3.20%)
After hours: 04:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close24.48
Open24.24
Bid24.00 x 1000
Ask26.32 x 900
Day's Range24.10 - 24.82
52 Week Range12.82 - 30.55
Volume102,055
Avg. Volume289,851
Market Cap895.271M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-2.29
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MIRM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Mirum Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Business Wire

    Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

    FOSTER CITY, Calif., August 12, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 521,739 shares, at a price to t

  • Business Wire

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., August 11, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,250 shares of common stock and 14,100 restricted stock units ("RSUs") to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the

  • Business Wire

    Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    FOSTER CITY, Calif., August 10, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting di

Advertisement
Advertisement